GLPcompareGLPcompare
DrugsPricesCompareShortagesEvidenceSupplementsWatchlist
HomeIndicationsChronic weight management
Indication

GLP-1 medications for Chronic weight management

GLP-1 medications for Chronic weight management, with sourced prices, shortage reports and study results.

Last checked · Oct 3, 2026 UTC
4approved
8in development

Approved for this use

Alphabetical by active ingredient. Approved uses depend on the specific brand and formulation.

GLP-1

Liraglutide

Victoza, Saxenda

Subcutaneous injection · Once daily

FDA shortage reportIn shortage

Published entry quote

~$372/mo

Generic liraglutide 3 mg pens (Saxenda generic), GoodRx coupon · GoodRx

Checked Sep 30, 2026

Price conditions

GoodRx coupon, lowest listed price for one carton of five 18 mg/3 mL pens

GoodRx lists brand Saxenda separately; this is its generic liraglutide listing (Teva launched the first generic GLP-1 for weight loss in August 2025). Prices vary by pharmacy.

Third-party reported price.

Checked Sep 30, 2026. Entry quotes are not estimates of ongoing treatment cost.

Prices, evidence & safety
Small-molecule GLP-1

Orforglipron

Foundayo

Oral tablet (any time of day, no food or water restriction) · Once daily

FDA shortage report

Published entry quote

from $149/mo

Foundayo (LillyDirect self-pay) · LillyDirect (Eli Lilly)

Checked Sep 30, 2026

Price conditions
GLP-1

Semaglutide

Ozempic, Wegovy, Wegovy HD, Rybelsus

Subcutaneous injection (Ozempic, Wegovy); oral tablet (Rybelsus, oral Ozempic, Wegovy pill) · Once weekly (injectable); once daily (oral)

FDA shortage report

Published entry quote

$149-$299/mo

Wegovy pill (oral semaglutide) via GoodRx · GoodRx

Checked Sep 30, 2026

Price conditions
GIP/GLP-1

Tirzepatide

Mounjaro, Zepbound

Subcutaneous injection · Once weekly

FDA shortage report

Published entry quote

$299-$449/28 days

Zepbound KwikPen (multi-dose pen) · LillyDirect (Eli Lilly)

Checked Sep 30, 2026

Price conditions

Investigational (pipeline)

Alphabetical by active ingredient. These entries are not FDA-approved for this category; open a record for the studied uses and evidence.

Small-molecule GLP-1Phase 3

Aleniglipron

Aleniglipron (investigational)

Oral tablet · Once daily

Investigational. No FDA-approved purchase option.

Study evidence & development
Amylin/GLP-1Phase 3
Other indications
Type 2 diabetes12Cardiovascular risk reduction4MASH3Chronic kidney disease in type 2 diabetes1Obstructive sleep apnea with obesity1All GLP-1 drugs
Browse
Drug classesManufacturers
GLPcompare is an informational data platform, not a medical provider or pharmacy. Nothing here is medical advice, a diagnosis, or a recommendation to start, stop, or change any treatment. Data is aggregated from public sources and can be incomplete or out of date. Always confirm with a licensed clinician and the current FDA label.
GLPcompareGLPcompare

The live, fully-cited reference for the GLP-1 ecosystem. Every figure traces to its source. Informational only, not medical advice.

Product

  • Drugs
  • Prices
  • Compare
  • Shortages
  • Evidence
  • Supplements

Legal

  • Methodology
  • About
  • News
  • Price updates
  • Privacy Policy
  • Terms of Service
  • Support

Some outbound links on GLPcompare are referral links. If you sign up or buy through one, we may earn a commission at no extra cost to you. It never changes the price you pay or the underlying data. Partner status and commission rates contribute to offer and provider value scores and can change their order. Every partner is labeled. Value scores are not medical recommendations; a higher-ranked offer is not necessarily the lowest price or the right product for you.

© 2026 GLPcompare. All rights reserved.

Fazier

self-pay cash, lowest dose; ~$25/mo with commercial coverage

The first oral small-molecule GLP-1 pill for weight loss; FDA-approved April 2026. LillyDirect self-pay ladder: $149 (0.8 mg), $199 (2.5 mg), $299 (5.5 and 9 mg), $299 (14.5 and 17.2 mg with a 45-day refill, else $349); the 2.5 mg and 5.5 mg doses are temporarily $149 and $199 through Dec 31, 2026.

30-day supply

Checked Sep 30, 2026. Entry quotes are not estimates of ongoing treatment cost.

Prices, evidence & safety

by dose; Novo Nordisk's self-pay price through a GoodRx coupon

The same oral semaglutide and prices as the NovoCare offer: $149 (1.5 mg), $199 (4 mg), $299 (9 mg and 25 mg), per Novo Nordisk's published self-pay ladder. FDA-approved product.

30-day supply

Third-party reported price.

Checked Sep 30, 2026. Entry quotes are not estimates of ongoing treatment cost.

Prices, evidence & safety

self-pay cash, by dose ($299 / $399 / $449)

Four weekly doses per pen; pen needles must be purchased separately. $299 at 2.5 mg, $399 at 5 mg, and $449 at higher doses under the Self Pay Journey offer with a refill within 45 days.

28-day supply

Checked Sep 30, 2026. Entry quotes are not estimates of ongoing treatment cost.

Prices, evidence & safety

Amycretin

Amycretin (investigational)

Subcutaneous injection and oral tablet (both in development) · Once weekly (injectable); once daily (oral)

Investigational. No FDA-approved purchase option.

Study evidence & development
Amylin/GLP-1FDA review

CagriSema

CagriSema (investigational)

Subcutaneous injection · Once weekly

Investigational. No FDA-approved purchase option.

Study evidence & development
GIPR antagonist/GLP-1Phase 3

MariTide

MariTide (investigational)

Subcutaneous injection · Monthly (or less frequent)

Investigational. No FDA-approved purchase option.

Study evidence & development
GLP-1/glucagonApproved in China; not FDA-filed

Mazdutide

Mazdutide (investigational in US)

Subcutaneous injection · Once weekly

Investigational. No FDA-approved purchase option.

Study evidence & development
Triple agonistPhase 3

Retatrutide

Retatrutide (investigational)

Subcutaneous injection · Once weekly

Investigational. No FDA-approved purchase option.

Study evidence & development
GLP-1/glucagonPhase 3

Survodutide

Survodutide (investigational)

Subcutaneous injection · Once weekly

Investigational. No FDA-approved purchase option.

Study evidence & development
GIP/GLP-1Phase 3

VK2735

VK2735 (investigational)

Subcutaneous injection (oral tablet in development) · Once weekly (injectable); once daily (oral)

Investigational. No FDA-approved purchase option.

Study evidence & development
Compare head-to-head